{"title":"循环microrna作为前列腺癌的生物标志物及其在前列腺良恶性分化中的意义","authors":"Kowsalya Ramprasad, Madhura Navule Siddappa, Manohar Chikkamoga Siddaiah, Manju Moorthy, Gopalakrishna Ramaswamy","doi":"10.4103/ua.ua_11_25","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Prostate cancer is among the most commonly diagnosed cancers in males worldwide. While Prostate-specific antigen (PSA) remains the front-line screening marker, it lacks sufficient diagnostic accuracy.</p><p><strong>Aims and objectives: </strong>So, in the quest for improved biomarkers, the expression profiles of circulating miRNAs have become increasingly significant. Hence, this study was undertaken to identify the miRNA profile unique to prostate cancer.</p><p><strong>Materials and methods: </strong>Using NanoString Human MicroRNA Arrays, we analyzed serum samples from three groups: patients with localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia.</p><p><strong>Results: </strong>Our analysis revealed distinct circulating miRNA expression patterns in prostate cancer patients compared to those with benign conditions. Specifically, miR-1272 and miR-1247-5p were significantly up-regulated (log2FC > 1, p < 0.05), whereas miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated (log2FC < -1, p < 0.05) in prostate cancer versus BPH. Additionally, when comparing localized and metastatic prostate cancer, hsa-miR-302d-3p and hsa-miR-1246 were notably up-regulated (log2FC > 3, <i>P</i> < 0.05). These specific miRNAs show potential for facilitating early diagnosis, enhancing risk stratification, and serving as non-invasive biomarkers for monitoring disease progression, thereby helping to reduce the need for unnecessary biopsies.</p><p><strong>Conclusions: </strong>Our findings suggest that circulating miRNAs could serve as minimally invasive biomarkers in prostatic cancer with a higher specificity and sensitivity, making them more effective at distinguishing between cancerous and benign conditions. However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.</p>","PeriodicalId":23633,"journal":{"name":"Urology Annals","volume":"17 3","pages":"192-200"},"PeriodicalIF":0.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366852/pdf/","citationCount":"0","resultStr":"{\"title\":\"Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate.\",\"authors\":\"Kowsalya Ramprasad, Madhura Navule Siddappa, Manohar Chikkamoga Siddaiah, Manju Moorthy, Gopalakrishna Ramaswamy\",\"doi\":\"10.4103/ua.ua_11_25\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Prostate cancer is among the most commonly diagnosed cancers in males worldwide. While Prostate-specific antigen (PSA) remains the front-line screening marker, it lacks sufficient diagnostic accuracy.</p><p><strong>Aims and objectives: </strong>So, in the quest for improved biomarkers, the expression profiles of circulating miRNAs have become increasingly significant. Hence, this study was undertaken to identify the miRNA profile unique to prostate cancer.</p><p><strong>Materials and methods: </strong>Using NanoString Human MicroRNA Arrays, we analyzed serum samples from three groups: patients with localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia.</p><p><strong>Results: </strong>Our analysis revealed distinct circulating miRNA expression patterns in prostate cancer patients compared to those with benign conditions. Specifically, miR-1272 and miR-1247-5p were significantly up-regulated (log2FC > 1, p < 0.05), whereas miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated (log2FC < -1, p < 0.05) in prostate cancer versus BPH. Additionally, when comparing localized and metastatic prostate cancer, hsa-miR-302d-3p and hsa-miR-1246 were notably up-regulated (log2FC > 3, <i>P</i> < 0.05). These specific miRNAs show potential for facilitating early diagnosis, enhancing risk stratification, and serving as non-invasive biomarkers for monitoring disease progression, thereby helping to reduce the need for unnecessary biopsies.</p><p><strong>Conclusions: </strong>Our findings suggest that circulating miRNAs could serve as minimally invasive biomarkers in prostatic cancer with a higher specificity and sensitivity, making them more effective at distinguishing between cancerous and benign conditions. However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.</p>\",\"PeriodicalId\":23633,\"journal\":{\"name\":\"Urology Annals\",\"volume\":\"17 3\",\"pages\":\"192-200\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366852/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urology Annals\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ua.ua_11_25\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urology Annals","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ua.ua_11_25","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：前列腺癌是世界范围内男性最常见的癌症之一。虽然前列腺特异性抗原（PSA）仍然是一线筛查标志物，但它缺乏足够的诊断准确性。目的和目的：因此，在寻找改进的生物标志物的过程中，循环mirna的表达谱变得越来越重要。因此，本研究旨在确定前列腺癌特有的miRNA谱。材料和方法：我们使用纳米串人类MicroRNA阵列分析了三组患者的血清样本：局限性前列腺癌、转移性前列腺癌和良性前列腺增生。结果：我们的分析揭示了前列腺癌患者与良性前列腺癌患者不同的循环miRNA表达模式。具体来说，miR-1272和miR-1247-5p在前列腺癌和前列腺增生中显著上调（log2FC bbb1, p < 0.05），而miR-337-3p、miR-191-5p和let-7a-5p在前列腺癌和前列腺增生中显著下调（log2FC < -1, p < 0.05）。此外，在比较局限性和转移性前列腺癌时，hsa-miR-302d-3p和hsa-miR-1246显著上调（log2FC > 3, P < 0.05）。这些特异性mirna显示出促进早期诊断、加强风险分层和作为监测疾病进展的非侵入性生物标志物的潜力，从而有助于减少不必要的活组织检查。结论：我们的研究结果表明，循环mirna可以作为前列腺癌的微创生物标志物，具有更高的特异性和敏感性，使其更有效地区分癌性和良性状况。然而，尽管前景光明，miRNA检测仍然昂贵，技术复杂，并且尚未标准化用于常规临床应用。因此，在更大的独立队列中进行进一步验证对于确认本研究中鉴定的mirna的诊断和预后效用至关重要。
Circulating microRNAs as biomarker in prostate cancer and their significance in the differentiation of benign and malignant conditions of the prostate.
Background: Prostate cancer is among the most commonly diagnosed cancers in males worldwide. While Prostate-specific antigen (PSA) remains the front-line screening marker, it lacks sufficient diagnostic accuracy.
Aims and objectives: So, in the quest for improved biomarkers, the expression profiles of circulating miRNAs have become increasingly significant. Hence, this study was undertaken to identify the miRNA profile unique to prostate cancer.
Materials and methods: Using NanoString Human MicroRNA Arrays, we analyzed serum samples from three groups: patients with localized prostate cancer, metastatic prostate cancer, and benign prostatic hyperplasia.
Results: Our analysis revealed distinct circulating miRNA expression patterns in prostate cancer patients compared to those with benign conditions. Specifically, miR-1272 and miR-1247-5p were significantly up-regulated (log2FC > 1, p < 0.05), whereas miR-337-3p, miR-191-5p, and let-7a-5p were significantly down-regulated (log2FC < -1, p < 0.05) in prostate cancer versus BPH. Additionally, when comparing localized and metastatic prostate cancer, hsa-miR-302d-3p and hsa-miR-1246 were notably up-regulated (log2FC > 3, P < 0.05). These specific miRNAs show potential for facilitating early diagnosis, enhancing risk stratification, and serving as non-invasive biomarkers for monitoring disease progression, thereby helping to reduce the need for unnecessary biopsies.
Conclusions: Our findings suggest that circulating miRNAs could serve as minimally invasive biomarkers in prostatic cancer with a higher specificity and sensitivity, making them more effective at distinguishing between cancerous and benign conditions. However, despite their promise, miRNA testing remains costly, technically complex, and not yet standardized for routine clinical use. Therefore, further validation in larger, independent cohorts is essential to confirm the diagnostic and prognostic utility of the miRNAs identified in this study.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
